
ACTU Stock Forecast & Price Target
ACTU Analyst Ratings
Bulls say
Actuate Therapeutics is attractive because elraglusib is showing broad synergy with orally dosed RAS inhibitors, including activity in 20 of 20 PDAC models and 4 of 4 daraxonrasib models, which supports a differentiated combination strategy against refractory tumors. The company also has a clear oral development path with FDA clearance for the Phase 1/2 study, expected 2H26 clinic entry, and the possibility of reaching the 210 ng/mL exposure threshold with one to two 250 mg tablets per day, while cash is modeled to last into 4Q27. Beyond pancreatic cancer, the pediatric program adds optionality: 53% response or disease control in 19 heavily pretreated patients, potential BEACON2 enrollment in 1H27, and possible PRV value of approximately $150M to $200M.
Bears say
Actuate Therapeutics is a clinical-stage biopharmaceutical company with no revenues in 2Q26 and 3Q26, underscoring a business still fully dependent on capital markets rather than product sales. Its losses remain persistent, at $0.20 per diluted share in 2Q26 and $0.14 in 3Q26, while full-year 2026 is projected to show another net loss of $0.57 per diluted share. Liquidity is also a concern, with cash of $4.44M at the end of 2Q26 and $2.10M at 3Q26, even after raising $11.8M, and management said additional capital will be needed beyond October 2027.
This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ACTU Analyst Forecast & Price Prediction
Start investing in ACTU
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Actuate Therapeutics Inc (ACTU) Forecast
ACTU Analyst Forecast & Price Prediction
Start investing in ACTU
Order type
Buy in
Order amount
Est. shares
0 shares